Cost Compliance Analysis of Real Therapy and INA-CBG’s of Chemotherapy Breast Cancer Inpatien At 2017 Dr. Moewardi Surakarta Hospital

Belinda Arbitya Dewi (Universitas Setia Budi)
Oetari Oetari (Universitas Setia Budi)
Tri Murti Andayani (Universitas Gadjah Mada)

Strada Jurnal Ilmiah Kesehatan (SJIK)
Vol. 10 No. 1 (2021): May

Observational research using a restrospective design from a hospital perspective. Samples of all claim files and medical records of breast cancer chemotherapy patients with codes C-4-13-I, C-4-13-II, and C-4-13-III in 2017. Analysis of the suitability of the cost of therapy with INA-CBG's rates with one sample t-test and factors that influence the cost of therapy with multivariate analysis. The results showed there were 113 treatment episodes of 72 patients, of which women aged <45 years were most affected. Difference between the real cost of hospitalized breast cancer and INA-CBG's rates in class 3 treatment C-4-13-I severity level Rp. -62,187,362, C-4-13-II of Rp. 6,159,896, C-4-13-III Rp. 64,042,570. Based on all severity values P <0.05, means the average cost of treating breast cancer with all different severity levels based on INA-CBG’s 2016 rates.